Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
1,716
Views
9
CrossRef citations to date
0
Altmetric
Author's View

Multiverse of immune microenvironment in metastatic colorectal cancer

Marc Van den Eyndea Department of Medical Oncology and Hepato-gastroenterology, Institut Roi Albert II, Cliniques Universitaires Saint-Luc/Université Catholique De Louvain (Uclouvain), Brussels, BelgiumView further author information
,
Bernhard Mlecnikb INSERM, Laboratory of Integrative Cancer Immunology, Paris, France;c Equipe Labellisée Ligue Contre Le Cancer, Paris, France;d Centre De Recherche Des Cordeliers, Sorbonne Université, Université De Paris, Paris, France;e Inovarion, Paris, FranceView further author information
,
Gabriela Bindeab INSERM, Laboratory of Integrative Cancer Immunology, Paris, France;c Equipe Labellisée Ligue Contre Le Cancer, Paris, France;d Centre De Recherche Des Cordeliers, Sorbonne Université, Université De Paris, Paris, FranceView further author information
&
Jérôme Galonb INSERM, Laboratory of Integrative Cancer Immunology, Paris, France;c Equipe Labellisée Ligue Contre Le Cancer, Paris, France;d Centre De Recherche Des Cordeliers, Sorbonne Université, Université De Paris, Paris, FranceCorrespondence[email protected]
View further author information
Article: 1824316 | Received 02 Sep 2020, Accepted 02 Sep 2020, Published online: 29 Sep 2020

References

  • Angell HK, Bruni D, Barrett JC, Herbst R, Galon J. The immunoscore: colon cancer and beyond. Clin Cancer Res. 2020;26:332–3. PMID: 31413009. doi:10.1158/1078-0432.ccr-18-1851.
  • Bindea G, Mlecnik B, Fridman WH, Galon J. The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. Semin Immunopathol. 2011;33:335–340. PMID: 21461991. doi:https://dx.doi.org/10.1007/s00281-011-0264-x.
  • Bruni D, Angell HK, Galon J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020. PMID: 32753728. doi::https://dx.doi.org/10.1038/s41568-020-0285-7.
  • Galon J, Bruni D. Tumor immunology and tumor evolution: intertwined histories. Immunity. 2020;52:55–81. PMID: 31940273. doi::https://dx.doi.org/10.1016/j.immuni.2019.12.018.
  • Galon J, Fox BA, Bifulco CB, Masucci G, Rau T, Botti G, Marincola FM, Ciliberto G, Pages F, Ascierto PA, et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med. 2016;14:273. PMID: 27650038 doi::https://dx.doi.org/10.1186/s12967-016-1029-z.
  • Kirilovsky A, Marliot F, El Sissy C, Haicheur N, Galon J, Pages F. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. Int Immunol. 2016;28:373–382. PMID: 27121213. doi::https://dx.doi.org/10.1093/intimm/dxw021.
  • Pages F, Galon J, Fridman WH. The essential role of the in situ immune reaction in human colorectal cancer. J Leukoc Biol. 2008;84:981–987. PMID: 18559950. doi:https://dx.doi.org/10.110777310.1189/jlb.1107773.
  • Angelova M, Mlecnik B, Vasaturo A, Bindea G, Fredriksen T, Lafontaine L, Buttard B, Morgand E, Bruni D, Jouret-Mourin A, et al. Evolution of metastases in space and time under immune selection. Cell. 2018;175:751–765 e716. PMID: 30318143 doi::https://dx.doi.org/10.1016/j.cell.2018.09.018.
  • Mlecnik B, Van den Eynde M, Bindea G, Church SE, Vasaturo A, Fredriksen T, Lafontaine L, Haicheur N, Marliot F, Debetancourt D, et al. Comprehensive intrametastatic immune quantification and major impact of immunoscore on survival. J Natl Cancer Inst. 2018;110:97–108. PMID: 28922789 doi::https://dx.doi.org/10.1093/jnci/djx123.
  • Van den Eynde M, Mlecnik B, Bindea G, Fredriksen T, Church SE, Lafontaine L, Haicheur N, Marliot F, Angelova M, Vasaturo A, et al. The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients. Cancer Cell. 2018;34:1012–1026 e1013. PMID: 30537506 doi::https://dx.doi.org/10.1016/j.ccell.2018.11.003.
  • El Sissy C, Kirilovsky A, Van den Eynde M, Musina AM, Anitei MG, Romero A, Marliot F, Junca A, Doyen J, Mlecnik B, et al. A diagnostic biopsy-adapted immunoscore predicts response to neoadjuvant treatment and selects patients with rectal cancer eligible for a watch-and-wait strategy. Clin Cancer Res. 2020. PMID: 32669377. doi:10.1158/1078-0432.CCR-20-0337
  • Buque A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Marabelle A, et al. Trial watch: immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology. 2015;4:e1008814. PMID: 26137403 doi:10.1080/2162402X.2015.1008814.
  • Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zucman-Rossi J, Zitvogel L, Kroemer G. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology. 2012;1:28–37. PMID: 22720209. doi::https://dx.doi.org/10.4161/onci.1.1.179382011ONCOIMM0018.
  • Vacchelli E, Eggermont A, Galon J, Sautes-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: monoclonal antibodies in cancer therapy. Oncoimmunology. 2013;2:e22789. PMID: 23482847. doi::https://dx.doi.org/10.4161/onci.22789.
  • Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Kroemer G. Trial watch: chemotherapy with immunogenic cell death inducers. Oncoimmunology. 2012;1:179–188. PMID: 22720239. doi: :https://dx.doi.org/10.4161/onci.1.2.190262011ONCOIMM0105.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.